These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31345101)

  • 1. Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.
    Reddy YNV; Iyer SR; Scott CG; Rodeheffer RJ; Bailey K; Jenkins G; Batzler A; Redfield MM; Burnett JC; Pereira NL
    J Am Heart Assoc; 2019 Aug; 8(15):e012943. PubMed ID: 31345101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
    Bayes-Genis A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Gastelurrutia P; Vila J; Peñafiel J; Gálvez-Montón C; Lupón J
    Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1075-84. PubMed ID: 26297179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients.
    Bayés-Genís A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2015 Feb; 65(7):657-65. PubMed ID: 25677426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction.
    Goliasch G; Pavo N; Zotter-Tufaro C; Kammerlander A; Duca F; Mascherbauer J; Bonderman D
    Eur J Heart Fail; 2016 Jan; 18(1):89-93. PubMed ID: 26725876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble neprilysin does not correlate with prognosis in pulmonary hypertension.
    Yoshihisa A; Yokokawa T; Misaka T; Oikawa M; Kobayashi A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Takeishi Y
    ESC Heart Fail; 2019 Apr; 6(2):291-296. PubMed ID: 30681298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered serum levels of neprilysin in heart failure patients with reduced ejection fraction.
    Nemcekova V; Malikova E; Goncalvesova E; Krenek P; Klimas J
    Bratisl Lek Listy; 2021; 122(1):28-33. PubMed ID: 33393317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients?
    Emrich IE; Vodovar N; Feuer L; Untersteller K; Nougue H; Seiler-Mussler S; Fliser D; Launay JM; Heine GH
    Nephrol Dial Transplant; 2019 Jan; 34(1):100-108. PubMed ID: 29635392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review.
    Ramanathan K; Padmanabhan G
    Indian Heart J; 2020; 72(1):14-19. PubMed ID: 32423555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population.
    Sangaralingham SJ; McKie PM; Ichiki T; Scott CG; Heublein DM; Chen HH; Bailey KR; Redfield MM; Rodeheffer RJ; Burnett JC
    Hypertension; 2015 Jun; 65(6):1187-94. PubMed ID: 25895587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure.
    McKie PM; Rodeheffer RJ; Cataliotti A; Martin FL; Urban LH; Mahoney DW; Jacobsen SJ; Redfield MM; Burnett JC
    Hypertension; 2006 May; 47(5):874-80. PubMed ID: 16585413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure: A Pilot Study.
    Bayés-Genís A; Barallat J; Pascual-Figal D; Nuñez J; Miñana G; Sánchez-Mas J; Galan A; Sanchis J; Zamora E; Pérez-Martínez MT; Lupón J
    JACC Heart Fail; 2015 Aug; 3(8):641-4. PubMed ID: 26251092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Smoking on Circulating Cardiac Troponin I Concentrations and Cardiovascular Events in the General Population: The HUNT Study (Nord-Trøndelag Health Study).
    Lyngbakken MN; Skranes JB; de Lemos JA; Nygård S; Dalen H; Hveem K; Røsjø H; Omland T
    Circulation; 2016 Dec; 134(24):1962-1972. PubMed ID: 27815376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients.
    Hwang HS; Kim JS; Kim YG; Lee YH; Lee DY; Ahn SY; Moon JY; Lee SH; Ko GJ; Jeong KH
    Front Cardiovasc Med; 2021; 8():684297. PubMed ID: 34212014
    [No Abstract]   [Full Text] [Related]  

  • 14. Determinants of N-terminal proatrial natriuretic peptide plasma levels in a survey of adult male population from Southern Italy.
    Rubattu S; Barbato A; Marchitti S; Iacone R; Di Castro S; Evangelista A; Stanzione R; Ippolito R; Sciarretta S; Palmieri L; Volpe M; Strazzullo P;
    J Hypertens; 2010 Aug; 28(8):1638-45. PubMed ID: 20453667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure.
    Vodovar N; Séronde MF; Laribi S; Gayat E; Lassus J; Januzzi JL; Boukef R; Nouira S; Manivet P; Samuel JL; Logeart D; Cohen-Solal A; Richards AM; Launay JM; Mebazaa A;
    JACC Heart Fail; 2015 Aug; 3(8):629-36. PubMed ID: 26251090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.
    Bibbins-Domingo K; Gupta R; Na B; Wu AH; Schiller NB; Whooley MA
    JAMA; 2007 Jan; 297(2):169-76. PubMed ID: 17213400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
    Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
    Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction.
    Nolte K; Herrmann-Lingen C; Platschek L; Holzendorf V; Pilz S; Tomaschitz A; Düngen HD; Angermann CE; Hasenfuß G; Pieske B; Wachter R; Edelmann F
    ESC Heart Fail; 2019 Apr; 6(2):262-270. PubMed ID: 30784226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.